References
Todorovic E, Dickson BC, Weinreb I. Salivary gland cancer in the era of routine next-generation sequencing. Head Neck Pathol. 2020;14:311–20. https://doi.org/10.1007/s12105-020-01140-4.
Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608. https://doi.org/10.1097/PAS.0b013e3181d9efcc.
Cipriani NA, Blair EA, Finkle J, et al. Salivary gland secretory carcinoma with high-grade transformation, CDKN2A/B loss, distant metastasis, and lack of sustained response to crizotinib. Int J Surg Pathol. 2017;25:613–8. https://doi.org/10.1177/1066896917709350.
Skálová A, Vanecek T, Majewska H, et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am J Surg Pathol. 2014;38:23–33. https://doi.org/10.1097/PAS.0000000000000088.
Luo W, Lindley SW, Lindley PH, et al. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature. Int J Clin Exp Pathol. 2014;7:9008–22.
Petersson F, Michal M, Grossmann P. A new hitherto unreported histopathologic manifestation of mammary analogue secretory carcinoma: “Masked MASC” associated with low-grade mucinous adenocarcinoma and low-grade in situ carcinoma components. Appl Immunohistochem Mol Morphol. 2016;24:6.
Skálová A, Ptáková N, Santana T, et al. NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is intraductal correct? Am J Surg Pathol. 2019;43:1303–13. https://doi.org/10.1097/PAS.0000000000001301.
Simpson RHW. Salivary duct carcinoma: new developments—morphological variants including pure in situ high grade lesions; proposed molecular classification. Head Neck Pathol. 2013;7:48–58. https://doi.org/10.1007/s12105-013-0456-x.
Taverna C, Baněčková M, Lorenzon M, et al. MUC4 is a valuable marker for distinguishing secretory carcinoma of the salivary glands from its mimics. Histopathology. 2020. https://doi.org/10.1111/his.14251.
Bell D, Ferrarotto R, Liang L, et al. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020;476:295–305. https://doi.org/10.1007/s00428-019-02640-7.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–47. https://doi.org/10.1038/s41571-018-0113-0.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
NJR discloses an advisory board function and receipt of honoraria from F. Hoffmann-La Roche AG. The “SalvGlandDx” panel has been developed by a grant from the Iten-Kohaut-Foundation/University Hospital Zurich Foundation to NJR. All other authors declare that they have no conflict of interest.
Informed consent
The patient provided a written informed consent in accordance with the Declaration of Helsinki.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rupp, N.J., Nemes, C., Rushing, E.J. et al. High‐grade Salivary Gland Adenocarcinoma Harboring ETV6-NTRK3 Fusion: Defined by Morphology or Molecular Aberration?. Head and Neck Pathol 15, 1082–1084 (2021). https://doi.org/10.1007/s12105-021-01297-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12105-021-01297-6